Docosa-13,16,19-trienoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Docosa-13,16,19-trienoic acid
• 化学式: C₂₂H₃₈O₂
• 分子量: 334.5
• InChiKey: WBBQTNCISCKUMU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8
• 重原子数：
  24
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] COMPOSITIONS AND METHODS OF DELIVERY OF DEUBIQUITINASE INHIBITORS<br/>[FR] COMPOSITIONS ET MÉTHODES D'ADMINISTRATION D'INHIBITEURS DE DÉUBIQUITINASE
  申请人：PHARMAKEA INC

  公开号：WO2015183987A1

  公开（公告）日：2015-12-03

  Described herein are compositions comprising deubiquitinase inhibitors in combination with albumin, methods of making such compositions, and methods of using such compositions in the treatment of conditions, diseases, or disorders that would benefit from inhibition of deubiquitinase activity.

  本文描述了含有去泛素化酶抑制剂与白蛋白组合的组合物，制备这种组合物的方法，以及利用这种组合物治疗需要抑制去泛素化酶活性的病症、疾病或紊乱的方法。
• Functional associative coatings for nanoparticles
  申请人：Hainfeld James F.

  公开号：US20080089836A1

  公开（公告）日：2008-04-17

  Described herein are nanoparticles that are coated with a bilayer of molecules formed from surface binding molecules and amphiphatic molecules. The bilayer coating self assembles on the nanoparticles from readily available materials/molecules. The modular design of the bilayer coated nanoparticles provides a means for readily and efficiently optimizing the properties of the bilayer coated nanoparticle compositions. Also described herein are uses of such nanoparticles in medicine, laboratory techniques, industrial and commerical applications.

  本文描述了一种纳米颗粒，其表面涂覆有由表面结合分子和两亲分子形成的双层分子层。该双层涂层可以自组装在纳米颗粒上，使用易得的材料/分子。双层涂层纳米颗粒的模块化设计提供了一种方便和高效地优化其性质的方法。此外，本文还描述了这种纳米颗粒在医学、实验室技术、工业和商业应用中的用途。
• Micelles For Drug Delivery
  申请人：Yang Yi-Yan

  公开号：US20100159019A1

  公开（公告）日：2010-06-24

  The invention provides a block copolymer comprising at least a first block and a second block. The first block comprises a plurality of temperature-sensitive monomeric units, a plurality of hydrophilic monomeric units and a plurality of targeting monomeric units, and the second block comprises a plurality of hydrophobic monomeric units. The second block comprises at least one pH-sensitive moiety.

  本发明提供了一种嵌段共聚物，包括至少第一嵌段和第二嵌段。第一嵌段包括多个温度敏感单体单元、多个亲水性单体单元和多个定位单体单元，第二嵌段包括多个疏水性单体单元。第二嵌段包括至少一个pH敏感基团。
• FLOWER INITIATION INDUCER
  申请人：SHISEIDO COMPANY LIMITED

  公开号：EP0823994A1

  公开（公告）日：1998-02-18

  An agent for inducing flower bud formation in plants comprising an unsaturated fatty acid having an oxo group and a hydroxy group, a hydroperoxy group, or an oxo group, a hydroxy group, and a hydroperoxy group; a method for preparing said agent for inducing flower bud formation; and, a method for inducing flower bud formation using said agent for inducing flower bud formation are provided.

  本发明提供了一种诱导植物花芽形成的药剂，该药剂由具有一个氧代基团和一个羟基基团、一个过氧基团或一个氧代基团、一个羟基基团和一个过氧基团的不饱和脂肪酸组成；还提供了一种制备所述诱导花芽形成药剂的方法；以及一种使用所述诱导花芽形成药剂诱导花芽形成的方法。
• MEDICINAL COMPOSITION FOR ORAL ADMINISTRATION
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP1188440A1

  公开（公告）日：2002-03-20

  The present invention is to provide a stabilized pharmaceutical composition for oral use containing 1-ethyl methylester 4-[[3-[p-(carboxyamidino)phenyl]-2-oxo-5-oxazolidinyl]meth yl]-1-piperazineacetate or a pharmaceutically acceptable salt thereof having an antagonistic action to GPIIb/IIIa receptor and an oily base. The present invention is to further provide a method for the manufacture of a stabilized pharmaceutical composition for oral use by compounding 1-ethyl methylester 4-[[3-[p-(carboxyamidino)phenyl]-2-oxo-5-oxazolidinyl]meth yl]-1-piperazineacetate or a pharmaceutically acceptable salt thereof with an oily base. The present invention is to furthermore provide a method for the stabilization of a pharmaceutical composition by compounding 1-ethyl methylester 4-[[3-[p-(carboxyamidino)phenyl]-2-oxo-5-oxazolidinyl]-met hyl]-1-piperazineacetate or a pharmaceutically acceptable salt thereof with an oily base.

  本发明旨在提供一种口服用稳定药物组合物，该组合物含有对GPIIb/IIIa受体具有拮抗作用的1-乙基甲酯4-[[3-[对(羧基氨基)苯基]-2-氧代-5-恶唑烷基]甲基]-1-哌嗪乙酸酯或其药学上可接受的盐以及油性碱。本发明进一步提供一种通过将 1-乙基甲酯 4-[[3-[p-(羧基脒基)苯基]-2-氧代-5-恶唑烷基]甲基]-1-哌嗪乙酸酯或其药学上可接受的盐与油性碱复配来制造口服用稳定药物组合物的方法。本发明进一步提供了一种稳定药物组合物的方法，即用油性碱复配 1-乙基甲酯 4-[[3-[对(羧基氨基)苯基]-2-氧代-5-恶唑烷基]甲基]-1-哌嗪乙酸酯或其药学上可接受的盐。